← Back to Search

Antipsychotic

Olanzapine for Cancer

Phase 3

Waitlist Available

Led By Charles L Loprinzi

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 28 days

Awards & highlights

Study Summary

This trial is testing if olanzapine can help reduce nausea and vomiting in patients with advanced cancer.

Eligible Conditions

Cancer
Blood Cancers

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 28 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 28 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Nausea

Secondary outcome measures

Daily episodes of vomiting/retching (number and time)

Daily nausea and vomiting scores

Incidence of adverse events with olanzapine

+1 more

Side effects data

From 2008 Phase 4 trial • 25 Patients • NCT00001656

31%

Increased appetite

31%

Hypersalivation

17%

tachycardia >100 beats/min (supine)

15%

Somnolence

15%

Constipation

Hypertension

Difficulty concentrating

Enuresis

Insomnia

Abnormal white blood count

100%

80%

60%

40%

20%

Study treatment Arm

Olanzapine Group

Clozapine Group

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm I (olanzapine)Experimental Treatment2 Interventions

Patients receive olanzapine PO every night on days 1-28.

Group II: Arm II (placebo, olanzapine)Active Control3 Interventions

Patients receive placebo PO every night on days 1-2 and olanzapine PO every night on days 3-28.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Olanzapine

2005

Completed Phase 4

~5480

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,153 Total Patients Enrolled

Mayo ClinicLead Sponsor

3,205 Previous Clinical Trials

3,766,784 Total Patients Enrolled

Charles L LoprinziPrincipal InvestigatorMayo Clinic in Rochester

3 Previous Clinical Trials

63 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you give us a ballpark number of people who have signed up for this experiment?

"That is correct. The listing on clinicaltrials.gov indicates that this trial is currently looking for 20 individuals from 1 site. The posting went up on 6/3/2022 and was last updated on the same day."

Answered by AI

Has the FDA cleared Olanzapine for public use?

"Olanzapine is considered to be a safe medication, as it has received a score of 3."

Answered by AI

Are recruitment efforts for this research ongoing at the moment?

"Yes, this clinical trial is looking for 20 additional patients and is currently recruiting at 1 site. The trial was first posted on 6/3/2022 and no new information has been added since then."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

2022. "Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05403580.